Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Kimberly
Murphy
Effective as of January 13,
2023, Kimberly Murphy resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”),
as well as from her positions as chair of the of the Nominating and Corporate Governance Committee of the Board and as member each of
the Compensation Committee and Audit Committee of the Board. Ms. Murphy’s departure was not the result of a disagreement with the
Company on any matter relating to the Company’s operations, policies or practices.
Appointment of Tim Ramdeen
Effective as of January 13,
2023, the Board appointed Tim Ramdeen to replace Ms. Murphy and serve as a member of the Board, chair of the Nominating and Corporate
Governance Committee of the Board and a member each of the Compensation Committee and Audit Committee of the Board.
Timothy R. Ramdeen has nearly
a decade of experience in private equity and hedge fund investing, capital markets, and company formation. Since June 2022, Mr. Ramdeen
has been founder and managing partner of Dharma Capital Advisors, an investment and advisory firm focused on early-stage private and public
companies. From March 2021 to March 2022, Mr. Ramdeen was co-founder, chief investment officer, and portfolio manager at Sixth Borough
Capital Management, a multi-stage, event-driven hedge fund focused on both private and public equities. Since 2022, Mr. Ramdeen has been
the co-founder of Amplexd Therapeutics, which is a women’s health/biotechnology company focused on providing low-cost, effective,
safe and accessible treatments for early cervical and HPV-related cancers worldwide. Mr. Ramdeen also serves as a corporate advisor/board
member to multiple early-stage companies and investment funds. Previously, Mr. Ramdeen was the fifth hire at Altium Capital Management
(“Altium”), a healthcare-focused investment firm, where from July 2019 to March 2021 he served as the sole investment analyst
on the private capital markets/special situations desk (privately-negotiated financings, direct investments, event-driven long/short,
and private to public investments in micro and small-cap companies). During his tenure at Altium, Mr. Ramdeen was instrumental in co-creating
the firm’s SPAC and reverse merger investment efforts and establishing extensive relationships with sell-side constituents, buy-side
counterparts, and hundreds of private and publicly traded companies across biotechnology, therapeutics, healthcare services, medical devices
and medtech. Mr. Ramdeen received his B.S. in Biology from Temple University, where he conducted scientific research across neurology,
oncology, and developmental biology. In addition, Mr. Ramdeen earned his MBA in Finance from NYU Stern School of Business.
In connection with his appointment,
Mr. Ramdeen will receive customary equity grants and cash compensation as more fully described under the section entitled “Director
Compensation” in the Company’s Proxy Statement for its 2022 annual meeting of stockholders filed with the SEC on July 18,
2022 pursuant to Section 14(a) of the Securities Exchange Act of 1934, as amended.
No family relationships exist
between Mr. Ramdeen and any other directors or executive officers of the Company. There are no transactions to which the Company is or
was a participant and in which Mr. Ramdeen has a material interest subject to disclosure under Item 404(a) of Regulation S-K.